Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Hormones and the Endocrine System >  Pancreatic hormone and blood sugar regulation >  Ertugliflozin

Ertugliflozin

Basic information Safety Supplier Related

Ertugliflozin Basic information

Product Name:
Ertugliflozin
Synonyms:
  • PF-04971729/PF04971729
  • 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose
  • Ertugliflozin, >=98%
  • Ertugliflozin : PF 04971729-00
  • Leuco methylthioninium
  • (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
  • Ertugliflozin Base
  • (1S,2S,3S,4R,5S)-(2,3,4-TRIS-BENZYLOXY-5-(4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL)-68-DIOXA-BICYCLO(3.2.1)OCT-1-YL)-METHANOL
CAS:
1210344-57-2
MF:
C22H25ClO7
MW:
436.88
Product Categories:
  • API
Mol File:
1210344-57-2.mol
More
Less

Ertugliflozin Chemical Properties

Melting point:
65 - 66oC
Boiling point:
630.5±55.0 °C(Predicted)
Density 
1.455
storage temp. 
Sealed in dry,Store in freezer, under -20°C
solubility 
DMSO (Slightly), Methanol (Slightly)
pka
12.95±0.70(Predicted)
form 
Solid
color 
White to Off-White
InChIKey
MCIACXAZCBVDEE-RDZQEHASNA-N
SMILES
[C@@]12(C3C=CC(Cl)=C(CC4C=CC(OCC)=CC=4)C=3)OC[C@@](CO)([C@@H](O)[C@H](O)[C@H]1O)O2 |&1:0,20,23,25,27,r|
More
Less

Ertugliflozin Usage And Synthesis

Uses

Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor used to treat type 2 diabetes.

Definition

ChEBI: Ertugliflozin is a diarylmethane.

Application

Ertugliflozin is a medication prescribed by veterinarians to help control insulin (blood sugar) levels in horses and ponies with insulin dysregulation (ID), equine metabolic syndrome (EMS), refractory hyperinsulinemia (high blood sugar), and hyperinsulinemic-associated laminitis (HAL), especially for horses that don't respond to changes in diet or other accepted management practices for metabolic syndromes. Ertugliflozin is not FDA-approved for equine use. It falls into the sodium-glucose co-transport-2 (SGLT2) inhibitors category and is administered orally at 0.05?mg/kg once daily for at least 30?days.

Mode of action

Ertugliflozin works by inhibiting the SGLT2 protein, which aids in the reabsorption of glucose in the kidneys, leading to excretion of more glucose through urine. Once daily doses of ertugliflozin have been shown to: Lower blood sugar levels, Correct insulin to normal or near-normal levels, and Reduce abnormal fat pads.

ErtugliflozinSupplier

DoEasy Pharma Co., Ltd. Gold
Tel
0571-0571-28806358 15397199029
Email
songxy@doepharma.com
Wellman Pharmaceutical Group Limited Gold
Tel
027-83778875 15807197853
Email
15807197853@163.com
Yaopu(Shanghai) Pharmaceutical Technology Co., Ltd Gold
Tel
021-50929289 86186163093
Email
sales@ypptech.com.cn
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
Jiangsu Vcare PharmaTech Co., Ltd.
Tel
13327700685
Email
sales@vcarepharmatech.com